On June 24, 2021, Machacek, Michelle; Altman, Michael D.; Huang, Chunhui; Reutershan, Michael H.; Sloman, David L.; Siliphaivanh, Phieng; Schneider, Sebastian E.; Yeung, Charles S.; Witter, David J.; Gibeau, Craig R.; Ye, Yingchun published a patent.Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Protein-arginine N-methyltransferase PRMT5 inhibitors for therapy. And the patent contained the following:
The present invention provides compounds and pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. These compounds can treat cancer, sickle cell, and hereditary persistence of fetal Hb mutations. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid
The Article related to methyltransferase prmt5 inhibitor pharmaceutical, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem